PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
about
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.Mechanisms and prevention of UV-induced melanoma.Role of Type I and II Interferons in Colorectal Cancer and Melanoma.Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma.Melanoma subtypes demonstrate distinct PD-L1 expression profiles.Implications of the tumor immune microenvironment for staging and therapeutics.A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis.Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy.Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
P2860
Q26797478-2C7D7BCE-DD2E-4544-83AD-9E4916E740C4Q28076473-1A9CF362-2CB6-4352-9F9B-5675FC3A6986Q34522172-36FAF621-80F8-4F80-996E-94485B0BFC0EQ38376371-D4A05707-DF13-4E3E-A3CF-400D0D728CDFQ38413904-F7FA111D-9A27-4D4E-BCB4-4E8DD1C92F21Q39432336-1F2F88F5-5F53-4F1F-91B9-431339CB4E7FQ41123286-665F4BE2-0579-4AFE-96FA-0496512B5B8AQ41577878-BCC47DBF-CF41-4A08-9C30-312289C2638DQ47107364-C1FDA6ED-CD95-4110-9ED6-DF97B72C28D8Q47592007-E9A348D5-FAF8-4708-A902-9127D649F98BQ48301194-E9CEB063-BADD-4D5C-92CD-18A841C4D47AQ48316187-C11D814A-F9A0-4D90-9E3E-3E216B0910F8Q49234966-A8F33E3C-4277-4B35-B86E-FAAAF509B6CCQ55476986-15458EDF-EDCC-4DC1-8DBB-1F28ACC06999Q57057523-6004F1DE-5BE7-4236-89BE-A7EA1371E8D0
P2860
PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
@en
type
label
PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
@en
prefLabel
PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
@en
P2093
P2860
P1476
PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
@en
P2093
Brandon S Luber
Drew M Pardoll
Haiying Xu
James R Eshleman
Janis M Taube
Jung H Kim
Katie Beierl
Ming-Tseh Lin
Nemanja Rodić
P2860
P304
P356
10.1158/2326-6066.CIR-14-0145
P577
2014-11-04T00:00:00Z